LANCE HOWARD LEOPOLD
Medical Practice in Dresher, PA
License number
Pennsylvania MD044489E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Dresher, PA 19025
Personal information
See more information about LANCE HOWARD LEOPOLD at radaris.comName
Address
Phone
1441 Catlin Way, Dresher, PA 19025
3051 Jolly Rd, Plymouth Mtng, PA 19462
Ambler, PA
305 Outlook St, Pittsburgh, PA 15227
3051 Jolly Rd, Plymouth Meeting, PA 19462
Professional information
See more information about LANCE HOWARD LEOPOLD at trustoria.com
Dr. Lance Leopold, Dresher PA - MD (Doctor of Medicine)
Dr. Lance Leopold, Dresher PA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
1441 Catlin Way, Dresher 19025
(866) 305-6063 (Fax)
(866) 305-6063 (Fax)
Certifications:
Hematology, 1994, Internal Medicine, 2001, Medical Oncology, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1441 Catlin Way, Dresher 19025
Temple University Hospital
3401 North Broad St, Philadelphia 19140
Temple University Hospital
3401 North Broad St, Philadelphia 19140
Education:
Medical School
Temple University
Graduated: 1987
Temple U
Temple & Fox Chase
Temple University
Graduated: 1987
Temple U
Temple & Fox Chase
Pulsatile Dosing Of Gossypol For Treatment Of Disease
Pulsatile Dosing Of Gossypol For Treatment Of Disease
US Patent:
2009001, Jan 8, 2009
Filed:
Jun 2, 2008
Appl. No.:
12/155327
Inventors:
Jon T. Holmlund - Carlsbad CA, US
Mel Sorensen - Malvern PA, US
Lance Leopold - Dresher PA, US
Dajun Yang - Rockville MD, US
Mel Sorensen - Malvern PA, US
Lance Leopold - Dresher PA, US
Dajun Yang - Rockville MD, US
Assignee:
Ascenta Therapeutics, Inc. - Malvern PA
International Classification:
A61K 31/11, A61K 38/20, A61P 35/00
US Classification:
424 852, 514700
Abstract:
This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
Pulsatile Dosing Of Gossypol For Treatment Of Disease
Pulsatile Dosing Of Gossypol For Treatment Of Disease
US Patent:
2009017, Jul 9, 2009
Filed:
Dec 10, 2008
Appl. No.:
12/332039
Inventors:
Jon T. Holmlund - Carlsbad CA, US
Mel Sorensen - Malvern PA, US
Lance Leopold - Dresher PA, US
Dajun Yang - Rockville MD, US
Mel Sorensen - Malvern PA, US
Lance Leopold - Dresher PA, US
Dajun Yang - Rockville MD, US
Assignee:
Ascenta Therapeutics, Inc. - Malvern PA
International Classification:
A61K 39/395, A61K 31/12, A61K 31/337, A61K 31/454, A61K 33/24, A61K 31/282, A61K 31/517, A61K 31/437, A61P 35/00
US Classification:
4241381, 514681, 514449, 514323, 424649, 514492, 5142664, 514283
Abstract:
This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
Pulsatile Dosing Of Gossypol For Treatment Of Disease
Pulsatile Dosing Of Gossypol For Treatment Of Disease
US Patent:
2010018, Jul 29, 2010
Filed:
Dec 10, 2009
Appl. No.:
12/635481
Inventors:
Jon T. Holmlund - Carlsbad CA, US
Mel Sorensen - Malvern PA, US
Lance Leopold - Dresher PA, US
Dajun Yang - Rockville MD, US
Mel Sorensen - Malvern PA, US
Lance Leopold - Dresher PA, US
Dajun Yang - Rockville MD, US
Assignee:
Ascenta Therapeutics, Inc. - Malvern PA
International Classification:
A61K 38/20, A61K 31/11, A61K 38/00, A61K 39/395, A61K 31/203, A61K 31/519, A61K 31/53, A61K 31/661, A61K 31/45, A61K 31/4196, A61K 31/285, A61K 38/50, A61K 31/7036, A61K 31/52, A61K 39/07, A61K 31/192, A61K 31/167, A61K 38/14, A61K 31/69, A61K 31/255, A61K 31/4152, A61K 31/505, A61K 31/282, A61K 33/24, A61K 31/7068, A61K 38/16, A61K 31/573, A61K 38/21, A61K 33/12, A61K 31/337, A61K 31/437, A61K 31/517, A61K 31/454, A61P 35/00
US Classification:
424 852, 514700, 514 2, 4241331, 514557, 5142621, 514245, 514114, 514328, 514383, 424623, 424 946, 514 43, 5142632, 4241841, 514569, 514618, 514 8, 514 64, 514517, 514404, 514269, 514492, 424649, 514 49, 514 12, 514179, 424 857, 424683, 514449, 514283, 5142664, 514177, 514323, 514285
Abstract:
This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
Spiro-Oxindole Mdm2 Antagonists
Spiro-Oxindole Mdm2 Antagonists
US Patent:
2012012, May 17, 2012
Filed:
Nov 11, 2011
Appl. No.:
13/294315
Inventors:
Shaomeng Wang - Saline MI, US
Yujun Zhao - Ann Arbor MI, US
Wei Sun - Ann Arbor MI, US
Sanjeev Kumar - Ann Arbor MI, US
Lance Leopold - Dresher PA, US
Laurent Debussche - Paris, FR
Cedric Barriere - Paris, FR
Jean-Christophe Carry - Paris, FR
Kwame Amaning - Paris, FR
Yujun Zhao - Ann Arbor MI, US
Wei Sun - Ann Arbor MI, US
Sanjeev Kumar - Ann Arbor MI, US
Lance Leopold - Dresher PA, US
Laurent Debussche - Paris, FR
Cedric Barriere - Paris, FR
Jean-Christophe Carry - Paris, FR
Kwame Amaning - Paris, FR
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
SANOFI - Paris
ASCENTA THERAPEUTICS, INC. - Malvern PA
SANOFI - Paris
ASCENTA THERAPEUTICS, INC. - Malvern PA
International Classification:
A61K 31/407, A61P 35/00, A61P 35/02, C07D 487/10
US Classification:
514409, 548410
Abstract:
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Combination Therapy For The Treatment Of Acute Leukemia And Myelodysplastic Syndrome
Combination Therapy For The Treatment Of Acute Leukemia And Myelodysplastic Syndrome
US Patent:
7727968, Jun 1, 2010
Filed:
Jun 11, 2007
Appl. No.:
11/811626
Inventors:
Jay Marshall Feingold - Wynnewood PA, US
Matthew L. Sherman - Newton MA, US
Lance H. Leopold - Dresher PA, US
Mark Berger - Merion Station PA, US
Matthew L. Sherman - Newton MA, US
Lance H. Leopold - Dresher PA, US
Mark Berger - Merion Station PA, US
Assignee:
Wyeth LLC - Madison NJ
International Classification:
A61K 31/70
US Classification:
514 34, 4241811, 514 45, 514 49
Abstract:
Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.